NCT05650879 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05650879
Title	ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (HER2)
Acronym	HER2
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Enliven Therapeutics
Indications	Her2-receptor positive breast cancer lung non-small cell carcinoma lung non-squamous non-small cell carcinoma Advanced Solid Tumor
Therapies	ELVN-002 ELVN-002 + Trastuzumab deruxtecan Ado-trastuzumab emtansine + ELVN-002
Age Groups:	senior \| adult
Covered Countries	USA \| ITA \| FRA \| ESP \| AUS

NCT05650879
Clinical Trial Detail